Advertisement

Novel Tissue Plasminogen Activators: Reteplase (R-PA)

  • Christoph Bode
  • Thomas K. Nordt
  • Benedikt Kohler
  • W. Douglas Weaver
  • Richard W. Smalling
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 193)

Abstract

Thrombolytic therapy has become an accepted form of treatment for acute myocardial infarction. The GUSTO I trial showed that mortality reduction correlates with early, complete, and sustained patency of the infarct-related coronary artery [1],[2]. Current thrombolytic regimens achieve patency 90 minutes after initiation of treatment in only about 81% of cases, and only about 54% experience complete (TIMI grade 3) reperfusion. These results are obtained 90 minutes after initiation of therapy, and earlier patency rates are even more disappointing. Early reocclusion further limits the preservation of left ventricular function. In addition, even though patients are carefully selected, bleeding, especially intracranial bleeding, is a feared side effect, limiting the applicability of this form of treatment. In order to improve the risk/benefit ratio of thrombolytic therapy for patients, a number of new thrombolytic agents are being developed, primarily with the aim of reducing mortality by establishing more rapid, more complete, and more stable coronary patency.

Keywords

Acute Myocardial Infarction Plasminogen Activator Thrombolytic Agent Sequential Probability Ratio Test TIMI Grade 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673, 1993.CrossRefGoogle Scholar
  2. 2.
    The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 329:1615, 1993.CrossRefGoogle Scholar
  3. 3.
    Kohnert U, Rudolph R, Verheijen JH, Weening-Verhoeff EJ, Stern A, Opitz U, Martin U, Lill H, Prinz H, Lechner M. Biochemical properties of kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng 5:93, 1992.PubMedCrossRefGoogle Scholar
  4. 4.
    Martin U, Bader R, Böhm E, Kohnert U, von Möllendorf E, Fischer S, Sponer G. BM 06.022: A novel recombinant plasminogen activator. Cardiovasc Drug Rev 11:299, 1993.CrossRefGoogle Scholar
  5. 5.
    Madison EL, Goldsmith EJ, Gerard RD, Gething MJ, Sambrook JF. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature 339:721, 1989.PubMedCrossRefGoogle Scholar
  6. 6.
    Martin U, Sponer G, Strein K. Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro. Blood Coagul Fibrinolysis 4:235, 1993.PubMedCrossRefGoogle Scholar
  7. 7.
    Martin U, Köhler J, Sponer G, Strein K. Pharmacokinetics of the novel recombinant plasminogen activator BM 06.022 in rats, dogs, and non-human primates. Fibrinolysis 6:39, 1992.CrossRefGoogle Scholar
  8. 8.
    Martin U, Fischer S, Kohnert U, Opitz U, Rudolph R, Sponer G, Stern A, Strein K. Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. Thromb Haemost 65:560, 1991.PubMedGoogle Scholar
  9. 9.
    Martin U, Sponer G, Strein K. Evaluation of thrombotic and systemic effects of the novel recombinant plasminogen activator BM 06.022 compared with alteplase, anistreplase, streptokinase and urokinase in a canine model of coronary artery thrombosis. J Am Coll Cardiol 19:433, 1992.PubMedGoogle Scholar
  10. 10.
    Martin U, Fischer S, Kohnert U, Rudolph R, Sponer G, Stern A, Strein K. Coronary thrombolytic properties of a novel recombinant plasminogen activator (BM 06.022) in a canine model. J Cardiovasc Pharmacol 18:111, 1991.PubMedCrossRefGoogle Scholar
  11. 11.
    Martin U, Sponer G, Strein K. Hirudin and sulotroban improve coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary artery thrombosis. Int J Hematol 56:143, 1992.PubMedGoogle Scholar
  12. 12.
    Martin U, Fischer S, Sponer G. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis. J Am Coll Cardiol 22:914, 1993.PubMedGoogle Scholar
  13. 13.
    Martin U, Sponer G, König R, Smolarz A, MeyerSabellek W. Strein K. Double bolus administration of the novel recombinant plasminogen activator (BM 06.022) improves coronary blood flow after reperfusion in a canine model of coronary thrombosis. Blood Coagul Fibrinolysis 3:139, 1992.PubMedCrossRefGoogle Scholar
  14. 14.
    Martin U, Sponer G, Strein K. Rapid reversal of canine thromboembolic pulmonary hypertension by bolus injection of the novel recombinant plasminogen activator BM 06.022. J Cardiovasc Pharmacol 7:365, 1993.Google Scholar
  15. 15.
    Martin U, Dalchau H, Sponer G. Effects of the novel recombinant plasminogen activator BM 06.022 on platelets and bleeding time in rabbits. Platelets 3:247, 1992.Google Scholar
  16. 16.
    Bode C, Kohler B, Nordt T, Peter K, Ruef J, von Hodenberg E, Small ing RW and the RAPLD Investigators. Thrombin activity during and after thrombolysis with reteplase or alteplase in patients with acute myocardial infarction (abstr). Circulation 90(Suppl. I):563, 1994.Google Scholar
  17. 17.
    Martin U, von Möllendorf E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. Clin Pharmacol Ther 50:429, 1991.PubMedCrossRefGoogle Scholar
  18. 18.
    Martin U, von MÖllendorf E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemost 66:569, 1991.PubMedGoogle Scholar
  19. 19.
    Neuhaus KL, von Essen R, Vogt A, Tebbe U, Rustige J, Wagner HJ, Appel KF, Stienen U, KÖnig R, Meyer-Sabellek W. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: Results of the German Recombinant Plasminogen Activator Study. J Am Coll Cardiol 24:55, 1994.PubMedCrossRefGoogle Scholar
  20. 20.
    Tebbe U, von Essen R, Smolarz A, Limbourg P, Rox J, Rustige J, Vogt A, Wagner J, Meyer-Sabellek W, Neuhaus KL. Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction. Am J Cardiol 72:518, 1993.PubMedCrossRefGoogle Scholar
  21. 21.
    Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, Habib G, Feldman R, Hohnloser S, Seals A, and the RAPID Investigators. More rapid, complete, and stable coronary thrombolysis with bolus administration ot reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 91:2725, 1995.PubMedGoogle Scholar
  22. 22.
    Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, Habib G, Feldman R, Hohnloser S and Seals A (or the RAPID Investigators. Improvement of global and regional LV-function by the bolus administration of recombinant plasminogen activator (r-PA) in acute myocardial infarction: A comparison with standard dose alteplase (abstr). Circulation 90(Suppl. I):562, 1994.Google Scholar
  23. 23.
    Bode C, Smalling RW, Sen S, Kalbfleisch J, Feldman R, Forycki F, Limbourg P, Mann D, Böhm E, Odenheimer DJ and the RAPID Investigators. Safety profile ot reteplase (r-PA) as compared to alteplase (rt-PA): Will there be fewer strokes? (abstr) Eur Heart J 15(Suppl. I):P3O96, 1994.Google Scholar
  24. 24.
    The INJECT Study Group. Randomized, double-blind comparison ot reteplase double-bolus administration with streptokinase in acute myocardial infarction (IN-JECT): Trial to investigate equivalence. Lancet 346:329, 1995.CrossRefGoogle Scholar
  25. 25.
    Bode C, Smalling RW, Berg G, Burnett C, Lorch G, Kalbfleisch J, Chernoff R, Christie L, Feldman R, Seals A, Weaver WD, and the RAPID Investigators. Randomized comparison of coronary thrombolysis achieved with double bolus reteplase (r-PA) and front-loaded “accelerated” alteplase (rt-PA) in patients with acute myocardial infarction. Circulation 94:891, 1996.PubMedGoogle Scholar
  26. 26.
    Purvis JA, McNeill AJ, Siddequi RA, Roberts MJD, McClements BM, McEneaney D, Campbell NPS, Khan MM, Webb SW, Wilson CM, Adgey AAJ. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction. J Am Coll Cardiol 23:6, 1994.PubMedGoogle Scholar
  27. 27.
    Bleich SD, Adgey AAJ, Pickering E, Hillis WS, Ghali M, Blankenship I, Madigan P, Bates E, Rees A, Love T, for the DOUBLE-Trial Investigators. An angiographic assessment of the efficacy and safety of front-loaded and bolus regimens of activase (Alteplase recombinant). The Double Bolus Lytic Efficacy Trial (abstr). Circulation 92(Suppl. I):415, 1995.Google Scholar
  28. 28.
    Verheugt FWA. Primary angioplasty for acute myocardial infarction: Is the balloon half full or halt empty? Lancet 347:1276, 1996.PubMedCrossRefGoogle Scholar
  29. 29.
    Grines CL, Browne KF, Marco J, Rothbaum D, Stone GW, O’Keefe J, Overlie P, Donohue B, Chelliah N, Timmis GC, Vlietstra RE, Strzelecki M, Pughrowicz-Ochocki S, O’Neill WW for the Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for myocardial infarction. N Engl J Med 328:673, 1993.PubMedCrossRefGoogle Scholar
  30. 30.
    Bode C, Matsueda GR, Hui KY, Haber E. Antibody-directed urokinase: A specific fibrinolytic agent. Science 229:765, 1985.PubMedCrossRefGoogle Scholar
  31. 31.
    Runge MS, Quertermous T, Zavodny PJ, Love TW, Bode C, Freitag M, Shaw SY, Huang PL, Chou CC, Mullins D. A recombinant chimeric plasminogen activator with high affiniry for fibrin has increased thrombolytic potency in vitro and in vivo. Proc Natl Acad Sci USA 88:10337, 1991.PubMedCrossRefGoogle Scholar
  32. 32.
    Runge MS, Harker LA, Bode C, Ruef J, Kelly AB, Marzec UM, Allen E, Caban R, Shaw SY, Haber E, Hanson SR. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation 94:1412, 1996.PubMedGoogle Scholar
  33. 33.
    Bode C, Hudelmayer M, Mehwald P, Bauer S, Freitag M, von Hodenberg E, Newell JB, Kübter W, Haber E, Runge MS. Fibrin targeted recombinant hirudin inhibits thrombus growth more efficiently than recombinant hirudin in vitro. Circulation 90:1956, 1994.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • Christoph Bode
  • Thomas K. Nordt
  • Benedikt Kohler
  • W. Douglas Weaver
  • Richard W. Smalling

There are no affiliations available

Personalised recommendations